Table 1.
Baseline characteristics of INSTI and NNRTI users in the discovery (INSTI users n = 730, NNRTI users n = 617) and validation cohort (INSTI users n = 209 and NNRTI users n = 90).
| Discovery Cohort | Validation Cohort | |||||
|---|---|---|---|---|---|---|
| INSTI | NNRTI | p-val | INSTI | NNRTI | p-val | |
| n = 730 | n = 617 | n = 209 | n = 90 | |||
| Age in years (IQR) | 51.0 (41.0–58.0) | 53.0 (46.0–60.0) | 0.0001 | 52.0 (45.0–61.0) | 54.0 (48.0–60.0) | 0.27 |
| Sex at birth (male) | 619 (84.8%) | 533 (86.4%) | 0.44 | 178 (85.2%) | 74 (82.2%) | 0.60 |
| BMI in kg/m2 Median (IQR) | 25.0 (22.7–27.7) | 24.7 (22.2–27.4) | 0.061 | 25.8 (23.0–28.4) | 25.1 (22.6–27.4) | 0.25 |
| Ethnicity (white) | 543 (74.4%) | 454 (73.6%) | 0.71 | 180 (86.1%) | 78 (86.7%) | 1.0 |
| Non-white | 185 (25.3%) | 163 (26.4%) | 29 (13.9%) | 12 (13.3%) | ||
| Missing | 2 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| HIV duration in years Median (IQR) | 10.8 (5.7–16.5) | 14.6 (9.9–20.4) | <0.0001 | 7.0 (3.5–12.7) | 14.1 (10.3–19.4) | <0.0001 |
| cART Duration in years Median (IQR) | 8.3 (4.7–13.4) | 11.5 (8.3–17.9) | <0.0001 | 6.0 (3.3–10.6) | 11.2 (7.8–17.9) | <0.0001 |
| Latest CD4 count (×106 cells/L) Median (IQR) | 740.0 (550.5–940.0) | 698.5 (550.2–917.5) | 0.096 | 660.0 (480.0–810.0) | 685.0 (512.5–867.5) | 0.16 |
| CD4 Nadir (×106 cells/L) Median (IQR) | 280.0 (160.0–422.5) | 240.0 (150.0–350.0) | <0.0001 | 290.0 (170.0–452.5) | 280.0 (145.0–365.0) | 0.072 |
| Viral Load Zenith (copies/mL) Median (IQR) | 97,000.0 (36,650.5–248,154.0) | 100,000.0 (40,000.0–262,000.0) | 0.36 | 156,748.0 (39,240.8–346,862.5) | 200,000.0 (70,264.0–387,309.0) | 0.20 |
| Currently smoking | 238 (32.6%) | 167 (27.1%) | 0.013 | 59 (28.2%) | 31 (34.4%) | 0.40 |
| Missing | 56 (7.7%) | 35 (5.7%) | 23 (11.0%) | 7 (7.8%) | ||
| Packyears Median (IQR) | 6.0 (0.0–22.0) | 4.5 (0.0–21.5) | 0.73 | 6.0 (0.0–28.5) | 10.3 (0.0–34.0) | 0.33 |
| Had Non-AIDS malignancy | 28 (3.8%) | 30 (4.9%) | 0.42 | 12 (5.7%) | 3 (3.3%) | 0.57 |
| Had previous cardiovascular disease | 214 (29.3%) | 209 (33.9%) | 0.077 | 66 (31.6%) | 29 (32.2%) | 1.0 |
| On lipid lowering medication | 141 (19.3%) | 112 (18.2%) | 0.62 | 40 (19.1%) | 22 (24.4%) | 0.35 |
| INSTI in use: | ||||||
| Dolutegravir | 435 (60%) | 77 (37%) | ||||
| Bictegravir | 164 (22%) | 39 (19%) | ||||
| Elvitegravir | 112 (15% | 90 (43%) | ||||
| Raltegravir | 19 (3%) | 3 (1%) | ||||
| NNRTI in use: | ||||||
| Nevirapine | 236 (38%) | 38 (42%) | ||||
| Doravirine | 164 (27%) | 5 (6%) | ||||
| Rilpivirine | 133 (22%) | 28 (31%) | ||||
| Efavirenz | 84 (14%) | 19 (21%) | ||||
Abbreviations: BMI: body mass index; cART: combination antiretroviral therapy; IQR: inter quartile range; INSTI: integrase strand transfer inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor. Cardiovascular disease was considered an official diagnosis of myocardial infarction, stroke, peripheral arterial disease and/or hypertension.